Genprex is a clinical stage gene therapy company committed to pioneering a new approach to treating cancer. We are developing potentially life-changing gene technologies based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles. The nanovesicles are then administered intravenously and are taken up by tumor cells where they express proteins that are missing or found in low quantities.
Our lead product candidate, Oncoprex™, targets non-small cell lung cancer. This initial cancer target represents about 85 percent of all lung cancers and causes more deaths each year than any other type of cancer. Lung cancer is the second most common form of cancer, and the five-year survival rate for late stage lung cancer has not improved substantially in a quarter century. Research indicates that our platform technologies may deliver a number of other cancer fighting genes, alone or in combination with other cancer therapies, to combat additional types of cancer.
We are committed to fighting cancer by continuing to develop unique and innovative gene therapies.
Our pioneering technologies are at the forefront of gene therapy and we stand behind our high-quality technology platform.
We have integrity and high ethical standards, and we believe in responsibly transforming the lives of those affected with cancer.
Our commitment, excellence in technology, and integrity behind what we do enables us to be trailblazers in the effort to change the lives of cancer patients.
We are a multidisciplinary team with broad business experience in the biotech and pharmaceutical industries with research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
We hire professionals with a high level of intellect, experience and competency with a strong commitment to deliver for cancer patients, the company and our stockholders.